Global Kidney Cancer Market Research Report – Segmentation by By Therapy (Targeted therapy, Immunotherapy, Chemotherapy, Radiation, and Surgery); By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, and Others); Region – Size, Share, Growth Analysis | Forecast (2024 – 2030)
Published: 2024 - January
Report Code: IM-16126
Format:
Region: Global
Chapter 1. GLOBAL KIDNEY CANCER MARKET – Scope & Methodology
1.1. Market Segmentation
1.2. Scope, Assumptions & Limitations
1.3. Research Methodology
1.4. Primary Sources
1.5. Secondary Sources
Chapter 2. GLOBAL KIDNEY CANCER MARKET – Executive Summary
2.1. Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2. Key Trends & Insights
2.2.1. Demand Side
2.2.2. Supply Side
2.4. Attractive Investment Propositions
2.5. COVID-19 Impact Analysis
Chapter 3. GLOBAL KIDNEY CANCER MARKET – Competition Scenario
3.1. Market Share Analysis & Company Benchmarking
3.2. Competitive Strategy & Development Scenario
3.3. Competitive Pricing Analysis
3.4. Supplier-Distributor Analysis
Chapter 4. GLOBAL KIDNEY CANCER MARKET - Entry Scenario
4.1. Regulatory Scenario
4.2. Case Studies – Key Start-ups
4.3. Customer Analysis
4.5. PESTLE Analysis
4.4. Porters Five Force Model
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Powers of Customers
4.4.3. Threat of New Entrants
4.4.4. Rivalry among Existing Players
4.4.5. Threat of Substitutes
Chapter 5. GLOBAL KIDNEY CANCER MARKET - Landscape
5.1. Value Chain Analysis – Key Stakeholders Impact Analysis
5.2. Market Drivers
5.3. Market Restraints/Challenges
5.4. Market Opportunities
Chapter 6. GLOBAL KIDNEY CANCER MARKET – By Theraphy
6.1. Targeted therapy
6.2. Immunotherapy
6.3. Chemotherapy
6.4. Radiation
6.5. Surgery
Chapter 7. GLOBAL KIDNEY CANCER MARKET – By Drug Class
-
- Angiogenesis Inhibitors
- mTOR Inhibitors
- Cytokines
Chapter 8. GLOBAL KIDNEY CANCER MARKET – By Distribution Channel
8.1. Hospitals
8.2. Clinics
8.3. Retail Pharmacies
8.4. Others
Chapter 9. GLOBAL KIDNEY CANCER MARKET, By Geography – Market Size, Forecast, Trends & Insights
9.1. North America
9.1.1. By Country
9.1.1.1. U.S.A.
9.1.1.2. Canada
9.1.1.3. Mexico
9.1.2. By Theraphy
9.1.3. By Drug Class
9.1.4. By Distribution Channel
9.1.5. Countries & Segments - Market Attractiveness Analysis
9.2. Europe
9.2.1. By Country
9.2.1.1. U.K.
9.2.1.2. Germany
9.2.1.3. France
9.2.1.4. Italy
9.2.1.5. Spain
9.2.1.6. Rest of Europe
9.2.2. By Theraphy
9.2.3. By Drug Class
9.2.4. By Distribution Channel
9.2.5. Countries & Segments - Market Attractiveness Analysis
9.3. Asia Pacific
9.3.2. By Country
9.3.2.2. China
9.3.2.2. Japan
9.3.2.3. South Korea
9.3.2.4. India
9.3.2.5. Australia & New Zealand
9.3.2.6. Rest of Asia-Pacific
9.3.2. By Theraphy
9.3.3. By Drug Class
9.3.4. By Distribution Channel
9.3.5. Countries & Segments - Market Attractiveness Analysis
9.4. South America
9.4.3. By Country
9.4.3.3. Brazil
9.4.3.2. Argentina
9.4.3.3. Colombia
9.4.3.4. Chile
9.4.3.5. Rest South America
9.4.2. By Theraphy
9.4.3. By Drug Class
9.4.4. By Distribution Channel
9.4.5. Countries & Segments - Market Attractiveness Analysis
9.5. Middle East & Africa
9.5.4. By Country
9.5.4.4. United Arab Emirates (UAE)
9.5.4.2. Saudi Arabia
9.5.4.3. Qatar
9.5.4.4. Israel
9.5.4.5. South Africa
9.5.4.6. Nigeria
9.5.4.7. Kenya
9.5.4.8. Egypt
9.5.4.9. Rest of MEA
9.5.2. By Theraphy
9.5.3. By Drug Class
9.5.4. By Distribution Channel
9.5.5. Countries & Segments - Market Attractiveness Analysis
Chapter 10. GLOBAL KIDNEY CANCER MARKET – Company Profiles – (Overview, Product Portfolio, Financials, Strategies & Developments)
10.1. Pfizer Inc
10.2. AstraZeneca
10.3. Bristol-Myers Squibb Company
10.4. Dr. Reddy's Laboratories Ltd
10.5. Lupin
10.6. Cipla Inc
10.7. Aurobindo Pharma
10.8. Fresenius SE & Co. KGaA
10.9. Sanofi
10.10. F. Hoffmann-La Roche Ltd
10.11. Abbott
Download Sample
Choose License Type
2850
5250
4500
1800
Frequently Asked Questions
The Kidney Market was valued at USD 7.81 billion and is projected to reach a market size of USD 11.29 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 5.4%.
The high-quality treatment at affordable and comparatively low-cost treatment is propelling the Kidney Cancer market industry.
Based on Distribution channel, the Kidney Market is segmented into Hospitals, Clinics and Pharmacies and Others.
North America is the most dominant region for the Kidney Market.
Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.
